Tech Company Financing Transactions

Remix Therapeutics Funding Round

On 12/9/2020, Remix Therapeutics raised $81 million in Series A funding from Foresite Capital, Alexandria Venture Investments and Arch Venture Partners.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1 Kendall Sq. Building 200
Cambridge, MA 02139
USA

Phone

Undisclosed

Website

www.remixtx.com

Email Address

Not Recorded

Overview

Remix Therapeutics is developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Powered by our proprietary REMaster technology platform, we can now create medicines with the unique ability to alter the way genes are read from the genome, correcting dysregulation or eliminating the gene message altogether.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Kevin Bitterman

        

Chief Operating Officer

Heather Wasserman

        

Chief Scientific Officer

Peter Smith

        

Vice President

Dominic Reynolds

        

Vice President

Jesse Smith

        

Vice President

Fred Vaillancourt

        

VP - Bus. Development

Alex Harding

        

Browse more venture capital transactions:

Prev: 12/8/2020: EPNS venture capital transaction
Next: 12/9/2020: Orca Security venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary